메뉴 건너뛰기
.. 내서재 .. 알림
소속 기관/학교 인증
인증하면 논문, 학술자료 등을  무료로 열람할 수 있어요.
한국대학교, 누리자동차, 시립도서관 등 나의 기관을 확인해보세요
(국내 대학 90% 이상 구독 중)
로그인 회원가입 고객센터 ENG
주제분류

추천
검색

논문 기본 정보

자료유형
학술저널
저자정보
이종후 (제주대학교) 송재욱 (성균관대학교 의과대학) 김이형 (경희대학교)
저널정보
연세대학교 의과대학 Yonsei Medical Journal Yonsei Medical Journal 제63권 제6호
발행연도
2022.6
수록면
511 - 519 (9page)
DOI
10.3349/ymj.2022.63.6.511

이용수

표지
📌
연구주제
📖
연구배경
🔬
연구방법
🏆
연구결과
AI에게 요청하기
추천
검색

초록· 키워드

오류제보하기
Purpose: Monoclonal antibodies against type 2 inflammatory pathways are currently promising therapeutics for severe asthma. The aim of this study was to determine how well type 2 (T2) inflammation-specific agents targeting interleukins reduce the rate ofasthma exacerbations (AE) in patients with severe asthma. Materials and Methods: We performed a systematic review and meta-analysis in accordance with PRISMA guidelines. A systematicliterature search was conducted in PubMed, Embase, and the Cochrane Central Register. The primary outcome was the reductionrate of annualized AEs. Results: We analyzed 17 studies comprising 11800 subjects. A total of 6197 patients received T2-specific agents (benralizumab,dupilumab, lebrikizumab, mepolizumab, reslizumab, and tralokinumab). Overall, T2-specific agents were significantly associatedwith a lower risk of AE, compared with placebo [rate ratio (RR) 0.58, 95% confidence interval (CI) 0.51 to 0.66]. Among all studiedagents, only tralokinumab did not demonstrate a reduction in AE. The efficacy of T2-specific agents in reducing AE was maintainedregardless of the pathway used. A subgroup analysis indicated that T2-specific agents further reduced the risk of AE in patients witheosinophil counts of ≥300 cells/μL (RR 0.41, 95% CI 0.32 to 0.53). Conclusion: Our findings suggest that T2-specific agents are significantly associated with a reduced rate of AE, compared withplacebo. Their efficacy appears to be enhanced in patients with eosinophil counts of ≥300 cells/μL.

목차

등록된 정보가 없습니다.

참고문헌 (0)

참고문헌 신청

함께 읽어보면 좋을 논문

논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!

이 논문의 저자 정보

최근 본 자료

전체보기

댓글(0)

0